Tsukasa Takahashi, Masatoshi Saito, Augusto F Schmidt, Haruo Usuda, Yuki Takahashi, Shimpei Watanabe, Takushi Hanita, Shinichi Sato, Yusaku Kumagai, Shota Koshinami, Hideyuki Ikeda, Sean Carter, Michael Clarke, Miss Erin L Fee, Nobuo Yaegashi, John P Newnham, Alan H Jobe, Matthew W Kemp
BACKGROUND: Antenatal steroids (ANS) are standard of care for women judged to be at imminent risk of preterm delivery. Worldwide, there is significant variation in ANS dosing strategy, selection for treatment criteria, and agent choice. This, combined with very limited optimization of ANS use per se means that treatment efficacy is highly variable and the rate of respiratory distress syndrome is decreased perhaps as little as 40%. In some cases, ANS use is associated with limited benefit and potential harm...
May 20, 2020: American Journal of Obstetrics and Gynecology